PremiumThe FlyEntrada Therapeutics price target lowered to $21 from $23 at Roth Capital Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating PremiumThe FlyEntrada receives authorization in the UK to initiate ELEVATE-45-201 study Entrada Therapeutics price target lowered to $23 from $29 at Roth MKM Entrada Therapeutics Reports Strong 2024 Financial Results PremiumRatingsOptimistic Outlook on Entrada Therapeutics: FDA Lifts Hold on ENTR-601-44, Paving Way for Key Trials Entrada Therapeutics Receives FDA Approval for DMD Study Entrada announces FDA removal of clinical hold on ENTR-601-44 
